Sanofi and Regeneron Rebuild Alliance with $8B Immunology Deal

Key points

• Sanofi pays Regeneron $1 billion upfront, with up to $7 billion in additional milestones, for four early-stage immunology programs.
• The assets target IL-4, IL-13, and IL-4 receptor alpha, including a bispecific antibody, to potentially replicate the success of Dupixent.
• REGN20423, a long-acting IL-13 antibody, is the most advanced asset, having begun a first-in-human trial in May 2026.
• The deal resolves a 2024 lawsuit where Regeneron alleged Sanofi violated their previous collaboration agreement by withholding commercialization data.
• Sanofi CEO Belén Garijo stated the primary goal of the new partnership is to rebuild trust with Regeneron after recent disputes.
• Regeneron retains an option to add Sanofi’s TSLP/IL-13 asset, lunsekimig, to the collaboration following phase 3 COPD data.

Background

This deal follows a period of tension between the two companies, including a 2024 lawsuit and public statements in July 2026 indicating talks for a new partnership. It also coincides with Regeneron’s recent presentation of data at the EASD conference regarding its obesity drug, trevogrumab, which showed potential to preserve muscle mass when combined with semaglutide.

How outlets are covering it

Fierce Biotech emphasizes the strategic need for Sanofi to find new growth drivers as Dupixent’s patent expires in 2031 and highlights the resolution of the 2024 lawsuit as a key factor in rebuilding trust. Axios focuses on the financial magnitude of the deal, describing it as an $8 billion expansion of their alliance to prepare for the patent cliff. Fierce Biotech also notes Regeneron’s concurrent efforts to position its obesity drug trevogrumab in a competitive market, a detail not covered by Axios.

Why it matters

The deal is critical for Sanofi’s long-term viability as it secures a pipeline of next-generation immunology drugs to replace the revenue from Dupixent, which generated 5.2 billion euros in Q2 2026. For Regeneron, the upfront payment and milestone structure provide significant capital to advance early-stage assets. The resolution of their legal dispute also stabilizes a key partnership in the biotech industry.

What to watch

Regeneron plans to begin clinical trials for the three preclinical assets in 2027. Sanofi and Regeneron will monitor phase 3 data for lunsekimig in COPD to determine if it should be added to the collaboration. The success of these new assets will be crucial in determining Sanofi’s ability to maintain its market position post-2031.